Niche focus Target a collaboration with Lysogene on neurodegenerative lysosomal storage disorders in pediatric populations, emphasizing gene therapy advances and potential for disease-modifying solutions.

Strategic partnerships Leverage their existing Sarepta Therapeutics collaboration and investor-backed progress to position complementary programs, co-development or technology licensing opportunities that accelerate clinical milestones.

Small team agility Engage with a compact organization (11-50 employees) to offer targeted, high-touch outreach and streamlined pilots or feasibility studies, highlighting rapid decision cycles and alignment with their near-term funding and development goals.

Funding readiness Align proposals with their funding profile (recent near $30M raised, revenue under $1M) to propose grant-ready or milestone-driven engagements, ensuring clear ROI and risk-sharing mechanisms.

Technology enablement Position support around their tech stack and operations, offering services that complement their digital infrastructure (CRM, data analytics, regulatory documentation, cloud hosting) to improve efficiency in clinical and regulatory workflows.